Impact of Early Corticosteroids on Preventing Clinical Deterioration in Non-critically Ill Patients Hospitalized with COVID-19: A Multi-hospital Cohort Study

Lakshmi Swaminathan · Scott Kaatz · Heather Chubb · Kim Tae · Mayur S. Ramesh · Raef Fadel · Cecilia Big · Jessica Jones · Scott A. Flanders · Hallie C. Prescott

Received: December 18, 2021 / Accepted: February 23, 2022 / Published online: March 10, 2022 © The Author(s) 2022

ABSTRACT

Introduction: While guidelines strongly recommend dexamethasone in critical COVID-19, the optimal threshold to initiate corticosteroids in non-critically ill patients with COVID-19 remains unclear. Using data from a state-wide COVID-19 registry, we evaluated the effectiveness of early corticosteroids for preventing clinical deterioration among non-critically ill patients hospitalized for COVID-19 and receiving non-invasive oxygen therapy.

Methods: This was a target trial using observational data from patients hospitalized for COVID-19 at 39 hospitals participating in the MI-COVID19 registry between March 16, 2020 and August 24, 2020. We studied the impact of corticosteroids initiated within 2 calendar days of hospitalization.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s40121-022-00615-x.

L. Swaminathan Internal Medicine, Division of Hospital Medicine, St. Joseph Mercy Hospital, Ann Arbor, MI, USA
S. Kaatz Division of Hospital Medicine, Henry Ford Hospital, Detroit, MI, USA
H. Chubb · K. Tae Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI), Ann Arbor, USA
M. S. Ramesh Division of Infectious Disease, Henry Ford Hospital, Detroit, MI, USA
R. Fadel Division of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA
C. Big Division of Infectious Disease, Beaumont Hospital-Dearborn, Dearborn, MI, USA
J. Jones Department of Pharmacy, Beaumont Hospital-Dearborn, Dearborn, MI, USA
S. A. Flanders Division of Hospital Medicine, University of Michigan, Ann Arbor, MI, USA
H. C. Prescott VA Center for Clinical Management Research, Ann Arbor, MI, USA

L. Swaminathan (✉) Division of Hospital Medicine, St. Joseph Mercy Hospital, 5301 McAuley Dr, Ypsilanti 48197, USA e-mail: Lakshmi_swaminathan@ihacares.com
hospitalization ("early steroids") versus no early steroids among non-ICU patients with laboratory-confirmed SARS-CoV2 receiving non-invasive supplemental oxygen therapy. Our primary outcome was a composite of in-hospital mortality, transfer to intensive care, and receipt of invasive mechanical ventilation. We used inverse probability of treatment weighting (IPTW) and propensity score-weighted regression to measure the association of early steroids and outcomes.

**Results:** Among 1002 patients meeting study criteria, 231 (23.1%) received early steroids. After IPTW, to balance potential confounders between the treatment groups, early steroids were not associated with a decrease in the composite outcome (aOR 1.1, 95%CI 0.8–1.6) or in any components of the primary outcome.

**Conclusion:** We found no evidence that early corticosteroid therapy prevents clinical deterioration among hospitalized non-critically ill COVID-19 patients receiving non-invasive oxygen therapy. Further studies are needed to determine the optimal threshold for initiating corticosteroids in this population.

**Keywords:** Corticosteroid therapy; COVID-19 therapeutics; SARS-COV2; Viral infections

**Key Summary Points**

While corticosteroids are proven beneficial in critical COVID-19, the role of early corticosteroids in non-critically ill hospitalized COVID-19 patients remains unclear.

Using data from a state-wide COVID-19 registry, we studied the impact of "early" corticosteroids (started within 2 days of hospitalization) versus "no early" steroids in preventing clinical deterioration among non-critically ill hospitalized COVID-19 patients.

In our cohort of 1002 COVID-19 patients receiving non-invasive oxygen therapy across 39 hospitals, early steroids were not associated with a decrease in-hospital mortality, transfer to intensive care, or intubation.

**INTRODUCTION**

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause substantial morbidity and mortality around the world [1]. Corticosteroids quickly emerged as a potential treatment option in COVID-19 because of their immunomodulatory effects and potential benefits in ARDS and septic shock from other etiologies [2, 3].

While initial guidance regarding corticosteroids was inconsistent, corticosteroids became standard-of-care for patients with severe COVID-19 in June 2020, after results of the RECOVERY randomized clinical trial showed a mortality reduction in oxygen-treated patients, with the greatest benefit for patients receiving invasive mechanical ventilation [4]. Following the RECOVERY trial press release, other steroid trials halted randomization, and the available trial data were pooled through the World Health Organization’s Rapid Evidence Appraisal for COVID-19 Therapies prospective meta-analysis—which confirmed the benefit of steroids in critically ill patients [4, 5]. All major practice guidelines were subsequently updated to recommend corticosteroids in COVID-19 patients receiving supplemental oxygen, with the strongest recommendation for patients receiving invasive mechanical ventilation [6–8].

While corticosteroids are clearly beneficial in critical COVID-19, the precise threshold of illness above which corticosteroids are indicated remains unclear. In particular, it is unclear whether corticosteroids are indicated in non-critically ill patients who are receiving low-flow oxygen therapy [9–11]. Most trials of early steroids in COVID-19 focused either exclusively on critically ill patients [5, 12–14] or included patients with heterogenous respiratory support [4], ranging from nasal canula oxygen to non-invasive ventilation, due to their pragmatic design.

Assessing the benefit of steroids in non-critically ill patients is important because corticosteroid therapy is known to have several potential side effects, including hyperglycemia and fluid retention. Pertinent to COVID-19,
Corticosteroids may also prolong viral shedding, as seen in viral pneumonias from severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome [15–17]. Finally, in observational studies of severe pneumonia caused by influenza viruses, corticosteroid therapy has been associated with worse clinical outcomes, including secondary bacterial infection and death [18]. Collectively, these data highlight the need for additional studies to evaluate the benefit of corticosteroids in non-critically ill patients hospitalized with COVID-19 [19, 20].

Therefore, using data from a state-wide, multi-hospital COVID-19 registry, we evaluated the impact of early corticosteroid use on preventing clinical deterioration in patients hospitalized with COVID-19 and receiving non-invasive oxygen therapy. We hypothesized that early corticosteroid treatment would be associated with a reduced mortality, transfer to intensive care, or receipt of invasive mechanical ventilation.

METHODS

Data Source: the MI-COVID19 registry

We utilized data from the MI-COVID-19 registry, a multi-hospital Continuous Quality Initiative sponsored by Blue Cross Blue Shield of Michigan and Blue Care Network, which aims to improve care for hospitalized patients with COVID-19. Over 40 Michigan hospitals voluntarily participate in MI-COVID-19 [21]. Trained abstractors at each hospital collected detailed data on adult patients hospitalized with COVID-19 using a structured data collection template. Patient characteristics, including demographics, medical history, comorbidities, physical findings, laboratory results, imaging studies, and medications, were abstracted directly from medical records. The term “corticosteroid” was harmonized across abstractors and across sites to be systemic (enteral or intravenous) corticosteroid therapy. Data abstracters collected data on the dose, route, type, and duration of systemic steroids directly from medication administration records in the electronic chart.

For hospitals unable to abstract all COVID-19 hospitalizations because of high volumes, hospitalizations were sorted by day of admission (e.g., Monday–Sunday) and, for each day, a pseudo-random number (minute of hospital discharge) was used to select a sample of patients for abstraction.

Cohort Inclusion/Exclusion Criteria

We identified all patients hospitalized with laboratory-confirmed SARS-CoV-2 infection (between March 16, 2020 and August 24, 2020) from MI-COVID-19 registry hospitals, who received supplemental oxygen during day 1 and/or day 2 of hospitalization, remained alive, and were in a non-ICU hospital location. We excluded patients with: (1) length of hospitalization <3 days; (2) no supplemental oxygen therapy during day 1 and/or day 2; (3) receipt of invasive mechanical ventilation or ICU level of care during day 1 and/or day 2; (4) admission via inter-hospital transfer; (5) who were pregnant; (6) transitioned to hospice within 3 h of hospital admission; or (7) discharged against medical advice. The goal of the inclusion and exclusion criteria was to emulate a target trial of corticosteroid therapy [22]. Because hospital days 1 and 2 were used for eligibility and strategy assignment, we ensured that no patients either met the study outcome (death, ICU, or invasive mechanical ventilation) or were ineligible for the study outcome (i.e., discharged alive from hospital) during days 1 or 2.

Treatment Assignment

Patients meeting study eligibility criteria were categorized into two treatment groups: early corticosteroids (treatment) and no early corticosteroids (comparison). Patients who received intravenous or oral dexamethasone, prednisone, methylprednisolone, or hydrocortisone within 2 days of arrival to the hospital or emergency department comprised the early steroid group. The comparison group included all patients who received no corticosteroids.
during the first 2 days of hospitalization. Pre-
hospital corticosteroid use and corticosteroids
use after day 2 were not considered in the study
group assignment.

Study Outcomes

The primary outcome was clinical deterioration,
defined as a composite of hospital mortality,
ICU transfer, or receipt of invasive mechanical
ventilation. Secondary outcomes included
individual components of the composite out-
come and hospital length of stay ≥ 7 days.

Subgroups

We examined the primary and secondary out-
comes in the overall cohort and for several
predefined subgroups by age (< 70 vs. ≥ 70 years), duration of symptoms prior to
hospitalization (< 7 days vs. ≥ 7 days) and
maximum oxygen requirement during hospital
days 1 and 2 (FiO₂ < 40% vs. FiO₂ ≥ 40%).

Statistical Analysis

All variables were summarized with standard
descriptive statistics, including mean and stan-
dard deviation (SD). Categorical variables were
summarized using percentages. Propensity score
regression adjustment was used to reduce selection bias. We used an inverse probability of
treatment weighting (IPTW) approach based on
patients’ propensity score (i.e., patients’ pre-
dicted probability of receiving corticosteroids
given their baseline covariates) to balance the
differences in baseline variables between treat-
gment groups [23].

A non-parsimonious multivariable logistic
regression model was constructed to estimate
each patient’s propensity score. Variables of the
propensity score (PS) model were prespecified
before outcome analyses, and included: (1)
patient demographics (age, gender, race, body
mass index); (2) co-morbidities (cardiac, pul-
monary, diabetes, cancer); (3) clinical symp-
toms on hospital presentation (fever, dyspnea);
(4) vital signs during day 1 and 2 of hospital-
ization (blood pressure, respiratory rate, highest
oxygen support); and (5) laboratory and
radiology features on hospital presentation
(creatinine, white blood cell count, and pres-
ence of imaging abnormalities). These covari-
ates were chosen based on clinical experience,
review of literature, and data available in the
COVID-19 registry [24]. We adjusted for date of
admission (measured in half-month epochs) to
take account of temporal trends in treatment
approach (e.g., hydroxychloroquine) and out-
comes independent of corticosteroids.

Group distributions were evaluated to
determine if the groups were comparable and
the IPTW was calculated and normalized. After
IPTW, the treatment and comparison groups
were similar except for the slight differences in
the proportion of admissions occurring during
the June 2020 epochs.

We converted different steroids into maxi-
mum prednisone equivalents to reduce hetero-
geneity and to create a standardized framework
for comparing steroid dose and duration
between treatment and control groups (Steroid
Conversion Calculator; MDCalc).

Characteristics between the unadjusted and
adjusted groups were compared using t tests for
continuous variables and Pearson’s chi-squared
tests for categorical variables. Propensity score-
weighted regression models were then fitted to
compare primary and secondary outcomes
between groups. Odds ratios with 95% confi-
dence intervals (OR, 95% CI) were reported, and
overall two-sided alpha-level of 0.05 was used to
determine statistical significance. Data were
analyzed using SAS software v.9.4 (SAS Institute,
Cary, NC, USA).

IRB Statement

MI-COVID-19 was deemed to be quality
improvement work and received the designa-
tion of non-regulated by the University of
Michigan institutional review board. Each hos-
pital participating in the Mi-COVID19 initiative
is required to have a signed Data Use Agreement
with the Coordinating Center for the collabo-
rative. The data submitted is a limited dataset
and is therefore sharable in an aggregated and
de-identified format.
RESULTS

Among 2217 hospitalizations for COVID-19 in the MI-COVID-19 registry during the study period, 1215 were excluded, leaving 1002 patients in our trial emulation (Fig. 1). Of 1002 eligible patients, 231 (23.1%) were treated with corticosteroids within 2 days of presentation (treatment group), while 771 (76.9%) were not (comparison group). Totals of 12 patients in the treatment and 55 patients in the control group had missing data needed for propensity score calculation and were excluded, leaving 935 patients for analysis.

Unadjusted patient characteristics are shown in Supplementary Table 1. Of the patients in the treatment group, 33% were black compared to 44% in the comparison group. Patients in the treatment group were also more likely to have heart disease or chronic lung disease and to have received corticosteroids prior to hospitalization. Totals of 162 (70.1%) patients in the treatment group and 342 (44.4%) in the comparison group received high-intensity supplemental oxygen therapy during the baseline/enrollment period [i.e., oxygen via nasal prongs or mask at ≥ 6 LPM or ≥ 40%FiO2; heated high flow nasal cannula (HHFNC); or non-invasive positive pressure ventilation (NIPPV)]. After inverse probability weighting, baseline demographic and clinical characteristics were not different between the treatment and comparison groups (Table 1).
| Table 1  | Characteristics of treatment versus comparison groups after inverse probability weighting |
|----------|----------------------------------------------------------------------------------------|
|          | Treatment (early steroids) ($n = 219$) | Comparison (no early steroids) ($n = 716$) | $p$ value |
| Patient characteristics and comorbidities | | | |
| Age, mean (SD) | 66.62 (14.40) | 65.56 (17.14) | 0.41 |
| BMI, mean (SD) | 31.29 (8.55) | 31.33 (8.37) | 0.94 |
| Female | 50.4% | 47.7% | 0.48 |
| Race: Black | 39.3% | 42.2% | 0.44 |
| Self-pay insurance | 3.0% | 2.4% | 0.67 |
| Prior steroids/immunosuppressive therapy | 11.6% | 11.5% | 0.96 |
| Diabetes-complicated | 12.5% | 11.1% | 0.57 |
| Heart disease | 40.6% | 39.6% | 0.79 |
| Chronic lung disease | 33.0% | 28.3% | 0.18 |
| Cancer | 9.5% | 8.7% | 0.70 |
| Moderate/severe kidney disease | 27.5% | 25.8% | 0.63 |
| Vitals, symptoms, and laboratory values during baseline/enrollment period | | | |
| Fever ($> 100.4 [F]$) | 36.5% | 36.9% | 0.91 |
| Dyspnea/shortness of breath | 80.4% | 78.2% | 0.48 |
| Elevated respiratory rate ($\geq 20$) | 94.2% | 91.5% | 0.19 |
| Decreased systolic blood pressure ($< 100$ mmHg) | 26.0% | 27.3% | 0.70 |
| High supplemental oxygen support first 2 days (low flow NC $\geq 6$ l or $\text{FiO}_2 \geq 40$, HHFNC, NIPPV) | 56.8% | 50.2% | 0.09 |
| Max. creatinine, mean (SD) | 1.68 (4.94) | 1.98 (7.17) | 0.57 |
| Max. white blood cell (WBC), mean (SD) | 7.82 (3.37) | 7.86 (6.42) | 0.94 |
| Imaging abnormalities on CXR or chest CT | 39.6% | 37.3% | 0.53 |
| Date of hospital admission | | | |
| Early March, late March admission | 3.3%, 30.3% | 0.7%, 43.9% | 0.003, < 0.001 |
| Early April, late April admission | 42.0%, 12.8% | 28.4%, 13.9% | < 0.001, 0.67 |
| Early May, late May admission | 6.2%, 2.9% | 6.1%, 3.0% | 0.95, 0.89 |
| Early June, late June admission | 0.1%, 1.8% | 3.3%, 0.3% | 0.01, 0.01 |
| Early July, late July admission | 0.2%, 0.3% | 0.2%, 0.3% | 0.92, 0.89 |
| Early August admission | 0.2% | 0.0% | 0.21 |
In the treatment group, the median time between symptom onset and start of corticosteroid therapy was 5 days. A total of 224 (97%) patients in the treatment group received prednisone or methylprednisolone, while 14 (6.1%) patients were treated with dexamethasone. During days with any corticosteroid treatment, patients in the treatment group received a median prednisone-equivalent of 75 mg/day, with a median treatment duration of 4 days. A total of 129 (16.7%) patients in the comparison group also received IV or oral steroids after day 2 of hospitalization. Supplemental Table 2 provides additional information on steroid use in treatment versus comparison groups.

The composite outcome of in-hospital mortality, transfer to the ICU, or receipt of MV occurred 28% in the treatment and 24% in the comparison group. In our IPTW multivariable model, early corticosteroids were not associated with decreased odds of the composite outcome (OR 1.1, 95% CI 0.8–1.6) in the overall cohort (Table 2), nor in any of the pre-specified subgroups defined by age, baseline FiO₂ requirement, or duration of symptoms (Table 3). Early corticosteroids were also not associated with a decrease in any of the individual measures of the primary outcomes of in-hospital mortality (OR 1.3, 95% CI 0.9–1.9), transfer to ICU level of care (OR 1.3, 95% CI 0.8–1.9), or receipt of invasive mechanical ventilation (OR 1.7, 95% CI 1.1–1.7). Early steroids were also not associated with a decreased odds of hospitalization length of stay ≥ 7 days (OR 0.9, 95% CI 0.6–1.2) (Table 2).

**DISCUSSION**

In this multi-center observational target trial emulation assessing the impact of early corticosteroid therapy in non-critically ill patients with COVID-19, we found no evidence that early corticosteroids prevent clinical deterioration. Specifically, we were unable to detect an association between early corticosteroids and reduced mortality, ICU transfer, or receipt of invasive mechanical ventilation.

Recommendations for the use of corticosteroids in non-critically ill hospitalized COVID-19 patients requiring oxygen therapy are largely based on data from the RECOVERY trial, a large, multi-hospital, randomized, open-label trial performed in the United Kingdom. This trial compared hospitalized patients who received up to 10 days of dexamethasone to those who received the standard of care. There was no difference in mortality with dexamethasone among patients who did not require oxygen at enrollment (RR 1.2; 95% CI 0.9–1.6). In

| Table 2 Association of early steroid treatment with primary and secondary outcomes |
|---------------------------------------------|-----------------|-----------------|-----------------|
| Treatment (early steroids) | Comparison (no early steroids) | Adjusted odds ratio | 95% confidence interval |
| Primary outcome | | | |
| Composite of in-hospital mortality, mechanical ventilation, and transfer to ICU level of care | 62/219 (28%) | 173/716 (24%) | 1.1 | (0.8, 1.6) |
| Secondary outcomes | | | |
| Individual components of primary outcome | | | |
| In-hospital mortality | 48 (22%) | 123 (17%) | 1.3 | (0.9, 1.9) |
| Transfer to ICU level of care | 32 (15%) | 101 (14%) | 1.3 | (0.8, 1.9) |
| Mechanical ventilation | 25 (11%) | 64 (9%) | 1.7 | (1.1, 2.7) |
| Length of stay ≥ 7 days | 93/219 (42%) | 317/716 (44%) | 0.9 | (0.6, 1.2) |

Odds ratios were generated from inverse probability of treatment weighted multivariable logistic regression models.
contrast, among patients who received supplemental oxygen (nasal canula, heated high-flow oxygen, and non-invasive positive pressure ventilation), but were not mechanically ventilated at enrollment, 23.3% of patients in the dexamethasone arm died within 28 days compared to 26.2% of patients in the standard of care arm (RR 0.8; 95% CI 0.7–0.9). However, because detailed data on the mode and amount of oxygen therapy were not collected, it is impossible to tease out the threshold at which corticosteroids are indicated from the RECOVERY trial.

The National Institute of Health COVID guidelines suggest dexamethasone can be withheld for hospitalized patients who require “minimal amounts of supplemental oxygen, but be given (either alone or in combination with remdesivir) in patients who require “increasing amounts of supplemental oxygen” [8]. Hence, we wanted to focus specifically on hospitalized COVID-19 patients requiring supplemental oxygen therapy to assess whether early use of steroids would be beneficial, and to identify the threshold of illness at which steroids would be helpful. Our study results are consistent with other observational studies that showed no difference in risk of intubation or mortality between non-critically ill hospitalized patients who received versus those that did not receive corticosteroids [11, 15, 25, 26].

There are many potential reasons for the discrepancy between our results and the findings of the oxygen-treated subgroup in RECOVERY. First, our study focused on a potentially less severely ill hospitalized population than the oxygen-treated patients in RECOVERY. Only 7% of patients in our treatment group received HHFNC therapy and none received NIPPV. Second, the RECOVERY trial specifically evaluated dexamethasone 6 mg orally or intravenously for up to 10 days or until hospital discharge, whichever came first. While the pooled meta-analysis from WHO included patients that received dexamethasone, hydrocortisone, and methylprednisolone, the RECOVERY trial contributed to 59% of patients in this meta-analysis. Many of the trials evaluating alternative glucocorticoids were terminated early after release of results from the RECOVERY trial. Thus, the evidence to support the use of hydrocortisone OR 0.7 (95% CI 0.4–1.1; P = 0.1) and methylprednisolone OR 0.9 (95% CI 0.3–2.9; P = 0.9) is not as robust as for dexamethasone OR 0.6 (95% CI 0.5–0.8; P < 0.001) [5]. Our study mostly evaluated methylprednisolone and prednisone (97% of all steroids used in the treatment group), and notably the average dose of methylprednisolone (75 mg in the treatment group) was twice as high as the equivalent dose of dexamethasone recommended in guidelines. Further, the

| Treatment | Comparison | Adjusted odds ratio | 95% confidence interval |
|-----------|------------|---------------------|------------------------|
| All Patients | 61/217 (28%) | 169/703 (24%) | 1.1 | (0.8, 1.6) |
| Duration of symptoms before hospitalization | | | | |
| < 7 days | 43/130 (33%) | 120/370 (32%) | 1.0 | (0.7, 1.6) |
| ≥ 7 days | 18/87 (21%) | 49/333 (15%) | 1.2 | (0.6, 2.2) |
| Age at hospitalization | | | | |
| < 70 years | 23/117 (20%) | 66/436 (15%) | 1.3 | (0.8, 2.2) |
| ≥ 70 years | 39/101 (39%) | 107/280 (38%) | 1.1 | (0.6, 1.8) |
| Max. supplemental oxygen during baseline/enrollment period | | | | |
| 1–6 L (< 40%) low-flow oxygen | 17/66 (26%) | 87/407 (21%) | 1.2 | (0.7, 2.1) |
| All other oxygen | 45/152 (30%) | 86/309 (28%) | 1.0 | (0.7, 1.7) |
median duration of steroids in our study was 4 days in the early steroid group, which was significantly shorter than the recommended duration of 10 days. This may suggest the importance of the choice, dose, and duration of steroids used in COVID-19 to blunt the inflammatory response consistent with results from other studies [27, 28].

Our study should be considered in the context of several limitations. First, it is an observational study in which the decision to administer corticosteroids was at the discretion of the treating clinicians and influenced by local hospital guidelines. We were careful to adhere to best practices for target trial emulation, and did not consider corticosteroid use after day 2 in the study group assignment. Thus, 16.7% patients in the comparison group received IV or oral steroids after day 2, which may have blunted the difference in mortality between treatment and comparison groups. However, because these patients likely received late corticosteroids in response to clinical deterioration, excluding them would have introduced bias. Instead, we used IPTW to balance potential confounders between the treatment and comparison groups. Similar designs have been used in large COVID-19 trials assessing vaccine efficacy and efficacy of COVID-19 therapeutics [29, 30]. While this approach was successful at balancing the a priori confounders (including pre-existing co-morbidities and use of systemic steroids pre-hospitalization), we cannot exclude the possibility of unmeasured confounding. Second, due to small sample sizes, we were unable to evaluate specific steroid regimens, and hence used maximum prednisone equivalents to standardize comparisons between the treatment and control groups. Similarly, inhaled corticosteroid use was out of the scope of this study. Third, while we did not balance on actual bacterial co-infection based on cultures, we balanced on clinical signs and symptoms suggestive of co-infection (fever, dyspnea, vital signs, WBC, imaging abnormalities) to ensure that our treated and untreated populations had equivalent likelihoods of bacterial co-infection. Few patients in our cohort presented with bacterial co-infection, as reported in a separate study [31]. Finally, this study occurred during the initial U.S. surge, when there was a relatively lower threshold to initiate invasive mechanical ventilation, due to concerns for aerosolization of SARS-CoV-2 with high-flow oxygen, and significant variation in treatments among our hospitals [32]. However, we ensured that the treatment groups were contemporaneous (and therefore subject to similar thresholds for ICU transfer and initiation of invasive mechanical ventilation) by including half-month epoch as a co-variate in our model.

CONCLUSIONS

Using data from a multihospital, state-wide registry, we found no association between early corticosteroid therapy and the composite outcome of in-hospital mortality, transfer to the ICU, and/or receipt of invasive mechanical ventilation in patients hospitalized for COVID-19 and requiring supplemental non-invasive oxygen therapy. Our study highlights the need for additional RCTs to determine the optimal timing, dose, and duration for corticosteroid therapy in non-invasive, mechanically ventilated patients with COVID-19.

ACKNOWLEDGEMENTS

We thank all BCBSM Collaborative Quality Initiatives and data abstractors that partnered together on data collection, and all hospitals and patients who were included in this study. We thank Elizabeth McLaughlin and Megan O’Malley for answering all our questions regarding the Mi-COVID19 registry.

Funding. This work was supported by Blue Cross and Blue Shield of Michigan and Blue Care Network, as part of their Value Partnerships program. This material is the result of work supported with resources and use of facilities at the Ann Arbor VA Medical Center. The views in this manuscript do not reflect the position or policy of AHRQ, the views of the Department of Veterans Affairs, or the US...
government. The Rapid Service Fee was funded by the Hospital Medicine Safety Consortium.

**Author contributions.** LS, SK, MR, RF, CB, JJ, SF, HP were involved in study design and conception. HC, KT were involved in data acquisition. Heather Chubb performed data analysis. LS, SK, HC, HCP were involved in data interpretation. LS and HP drafted the manuscript. LS, SK, MR, RF, CB, JJ, SF, HP were involved in critical manuscript review. All authors participated in final manuscript revision and take responsibility for the integrity of the data and the accuracy of the data analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work, and have given their approval for this version to be published.

**Disclosures.** Scott Flanders reports grants from Blue Cross Blue Shield of Michigan (BCBSM), grants from Agency for Healthcare Research and Quality (ARHQ), during the conduct of the study. Scott Kaatz reports consulting fees from Janssen, Pfizer, Portola/Alexion, Bristol Myer Squibb, Norvartis, CSL Behring, Gilead & BMS. Scott Kaatz serves in a leadership or fiduciary Leadership or fiduciary role at Anticoagulation Forum & Medical Scientific Advisory Board for the National Blood Clot Alliance. Hallie Prescott reports grants from BCBSM during the conduct of the study; grants from VA HSR&D, grants from AHRQ, outside the submitted work; and she serves on Surviving Sepsis Campaign Guidelines Panels for Adult Sepsis and COVID. Lakshmi Swaminathan, Mayur Ramesh, Raef Fadel, Cecilia Big, Jessica Jones, HC, KT have no conflicts to disclose.

**Compliance with ethics guidelines.** MiCOVID-19 was deemed to be quality improvement work and received the designation of non-regulated by the University of Michigan institutional review board. Each hospital participating in the MiCOVID19 initiative is required to have a signed Data Use Agreement with the Coordinating Center for the collaborative. The data submitted is a limited data set and is therefore sharable in an aggregated and de-identified format.

**Data availability.** The MiCOVID19 data registry is proprietary, and all authors abided by the data privacy agreements in place. Statistical code for the study is available on reasonable request. The data sets are not available due to the proprietary nature of MI-COVID 19 data registry. The registry has a process for submitting data requests by participating hospitals. All applications for data analysis vetted by data/design publication committee and prioritized based on alignment with the mission of the collaborative.

**Open Access.** This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

**REFERENCES**

1. (No Title). https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200512-covid-19-sitrep-113.pdf?sfvrsn=feac3b6d_2. Accessed 12 May 2020.

2. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934. https://doi.org/10.1001/jamainternalmed.2020.0994.
3. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–5. https://doi.org/10.1016/S0140-6736(20)30317-2.

4. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19—preliminary Report. N Engl J Med. 2020. https://doi.org/10.1056/nejmoa2021436.

5. Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–41. https://doi.org/10.1001/jama.2020.17023.

6. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 2021. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed 13 Feb 2021.

7. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Accessed June 3, 2020. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

8. COVID-19 Treatment Guidelines. 2021. https://www.covid19treatmentguidelines.nih.gov/. Accessed 13 Feb 2021.

9. Majmundar M, Kansara T, Lenik JM, et al. Efficacy of corticosteroids in non-intensive care unit patients with [COVID]-19 pneumonia from the New York Metropolitan region. Adrish M, ed. PLoS ONE. 2020;15(9):e0238827. https://doi.org/10.1371/journal.pone.0238827.

10. Tortajada C, Colomer E, Andreu-Ballester JC, Esparcia A, Oltra C, Flores J. Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: effect of corticosteroids on mortality and intensive care unit admission in patients with COVID-19 according to patients’ oxygen requirements. J Med Virol. 2021;93(3):1817–23. https://doi.org/10.1002/jmv.26635.

11. Keller MJ, Kitsis EA, Arora S, et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. J Hosp Med. 2020;15(8):489–93. https://doi.org/10.12788/jhm.3497.

12. Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13):1298–306. https://doi.org/10.1001/jama.2020.16761.

13. Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–29. https://doi.org/10.1001/jama.2020.17022.

14. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–16. https://doi.org/10.1001/jama.2020.17021.

15. Tlayjeh H, Mish OH, Enani MA, et al. Association of corticosteroids use and outcomes in [COVID]-19 patients: A systematic review and meta-analysis. J Infect Public Health. 2020;13(11):1652–63. https://doi.org/10.1016/j.jiph.2020.09.008.

16. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):57–67. https://doi.org/10.1164/rcrm.201706-1172oc.

17. Lee N, Chan KCA, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus [RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304–9. https://doi.org/10.1016/j.jcv.2004.07.006.

18. Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis. Crit Care Med. 2020;48(2):E98–106. https://doi.org/10.1097/CCM.0000000000004093.

19. Prescott HC, Rice TW. Corticosteroids in [COVID]-19 [ARDS]. JAMA. 2020;324(13):1292. https://doi.org/10.1001/jama.2020.16747.

20. Matthay MA, Thompson BT. Dexamethasone in hospitalised patients with [COVID]-19: addressing uncertainties. Lancet Respir Med. 2020;8(12):1170–2. https://doi.org/10.1016/s2213-2600(20)30503-8.

21. Mi-COVID19 Initiative | Michigan Hospital Medicine Safety Consortium. 2021. https://www.mihms.org/quality-initiatives/mi-covid19-initiative. Accessed 13 Feb 2021.

22. Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70–5. https://doi.org/10.1016/j.jclinepi.2016.04.014.
23. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–79. https://doi.org/10.1002/sim.6607.

24. Mudatsir M, Fajar JK, Wulandari L, et al. Predictors of COVID-19 severity: a systematic review and meta-analysis. F1000Research. 2021;9:1107. https://doi.org/10.12688/f1000research.26186.2.

25. Tran VT, Mahévas M, Bani-Sadr F, et al. Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. Clin Microbiol Infect. 2020. https://doi.org/10.1016/j.cmi.2020.11.035.

26. Dupuis IdC, De Montmollin E, Buetti N, et al. Impact of early corticosteroids on 60-day mortality in critically ill patients with COVID-19: a multi-center cohort study of the OUTCOMEREA network. Published online. 2021. https://doi.org/10.1371/journal.pone.0255644.

27. Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021;72(9):e373–81. https://doi.org/10.1093/cid/ciaa1177.

28. Monreal E, Sainz de la Maza S, Natera-Villalba E, et al. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2021;40(4):761–9. https://doi.org/10.1007/S10096-020-04078-1/FIGURES/2.

29. Ioannou GN, Locke ER, O’Hare AM, et al. COVID-19 vaccination effectiveness against infection or death in a National U.S. Health Care system: a target trial emulation study. Ann Intern Med. 2021. https://doi.org/10.7326/M21-3256.

30. Gupta S, Wang W, Hayek SS, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41–51. https://doi.org/10.1001/jamainternmed.2020.6252.

31. Vaughn VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital Cohort Study. Clin Infect Dis. 2021;72(10):e533–41. https://doi.org/10.1093/CID/CIAA1239.

32. Chopra V, Flanders SA, Vaughn V, et al. Variation in COVID-19 characteristics, treatment and outcomes in Michigan: an observational study in 32 hospitals. BMJ Open. 2021. https://doi.org/10.1136/BMJOPEN-2020-044921.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.